Skip Navigation
Skip to contents

JYMS : Journal of Yeungnam Medical Science

Indexed in: ESCI, Scopus, PubMed,
PubMed Central, CAS, DOAJ, KCI
FREE article processing charge
OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > Browse Articles > Author index
Search
Won Sik Lee 4 Articles
Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen
Hee-Jeong Cho, Sang-Kyung Seo, Dong Won Baek, Sung-Woo Park, Yoo-Jin Lee, Sang-Kyun Sohn, Ho-Sup Lee, Won Sik Lee, Ji Hyun Lee, Sung Hyun Kim, Joon-Ho Moon
Yeungnam Univ J Med. 2018;35(1):76-83.   Published online June 30, 2018
DOI: https://doi.org/10.12701/yujm.2018.35.1.76
  • 6,340 View
  • 51 Download
  • 3 Crossref
AbstractAbstract PDF
Background
Elderly patients with multiple myeloma (MM) are vulnerable to adverse events (AEs). This study evaluated adherence to chemotherapy and treatment outcomes in elderly patients treated with a frontline bortezomib (BTZ), melphalan, and prednisone (VMP) regimen and regimens without BTZ.
Methods
One-hundred and forty elderly patients who were diagnosed with MM from March 2007 to March 2015 were included in this retrospective study. To evaluate regimen adherence, patients who were treated with more than 4 cycles were assigned to the good adherence group.
Results
Among the 140 patients, 71 were treated with a frontline VMP and 69 with non-BTZ regimens. The median age was 71 years (range, 65-90 years). The VMP group showed a higher complete response rate than the non-BTZ group: 26.8% vs. 7.2%. More patients in the VMP group achieved ≥very good partial response (VGPR) and ≥PR. In the VMP group, 27 patients (38.0%) received less than 4 cycles. The VMP good adherence group showed a higher 3-year overall survival (OS) rate (70.9%) than the poor adherence group (60.2%, p=0.059). In the multivariate analysis, treatment with ≥4 cycles of VMP was a favorable factor for OS.
Conclusion
A good adherence to a frontline VMP regimen resulted in favorable long-term survival. Adequate management of AEs will be needed to achieve favorable outcomes in elderly patients with MM.

Citations

Citations to this article as recorded by  
  • Solomon Islands Oncology Unit: Sustainability in Terms of Outcomes
    Dylan Bush, Mark Love, Hugo Bugoro, Nixon Panda
    JCO Global Oncology.2024;[Epub]     CrossRef
  • Real World Adherence to and Persistence With Oral Oncolytics in Multiple Myeloma: A Systematic Review and Meta-analysis
    Abdallah Y. Naser, Richard Ofori-Asenso, Safaa Al Awawdeh, Sami Qadus, Hassan Alwafi, Danny Liew
    Clinical Lymphoma Myeloma and Leukemia.2022; 22(10): 760.     CrossRef
  • Oral therapy adherence and satisfaction in patients with multiple myeloma
    Marine Solano, Etienne Daguindau, Cyril Faure, Pierre Loriod, Coline Pain, Anne-Cécile Maes, Pauline Marguet, Marie Kroemer, Anne Rumpler, Jean Fontan, Eric Deconinck, Samuel Limat, Anne-Laure Clairet
    Annals of Hematology.2021; 100(7): 1803.     CrossRef
A Case of Intravesical Cidofovir Treatment of BK Virus-Associated Hemorrhagic Cystitis after Allogeneic Peripheral Blood Stem Cell Transplantation.
Seong Hun Kang, Hwa Jeong Lee, Ye Su Jang, Jun Ho Ji, Sun Ah Lee, Won Sik Lee, Jung Lim Lee, Kyung Hee Lee
Yeungnam Univ J Med. 2009;26(2):143-147.   Published online December 31, 2009
DOI: https://doi.org/10.12701/yujm.2009.26.2.143
  • 1,843 View
  • 7 Download
AbstractAbstract PDF
Hemorrhagic cystitis (HC) is a common complication after allogeneic transplantation. Early posttransplant HC occurs in association with cyclophosphamide, while later on HC results from viral infections such as polyomavirus BK (BKV) and adenovirus. We report here the case of a 57-year-old woman who received an instillation of cidofovir into the bladder for the treatment of hemorrhagic cystitis after allogeneic peripheral stem cell transplantation for her acute myeloid leukemia. Cyclophosphamide and busulfan were used as conditioning treatments. Cyclosporin was administered daily. On the 71st day after transplantation, the patient developed acute severe hemorrhagic cystitis, and BK virus was demonstrated in the urine samples using polymerase chain reaction. Her urinary symptoms did not improve in spite of palliative treatment, but a response was evident after intravesical cidofovir treatment.
A Case of Primary Mucinous Cystadenocarcinoma.
Jun Ho Ji, Hwa Jung Lee, Seung Chan Park, Jung Chul Park, Eun Jung Choi, Hye Jin Seo, Won Sik Lee, Jung Lim Lee, Byung Jo Bae, Kyung Rak Shon, Kyung Hee Lee
Yeungnam Univ J Med. 2008;25(2):134-138.   Published online December 31, 2008
DOI: https://doi.org/10.12701/yujm.2008.25.2.134
  • 1,884 View
  • 1 Download
  • 1 Crossref
AbstractAbstract PDF
Primary retroperitoneal mucinous cystadenocarcinoma is a very rare malignancy, and little is known concerning its pathogenesis, optimal treatment, and prognosis. A 29-year-old pregnant woman (21 weeks) presented with abdominal discomfort. CA 19-9, CA 125, and CEA were normal. Abdominal CT scanning revealed a 19x15x13 cm retroperitoneal tumor. Exploratory laparotomy and tumor excision were performed. Mucinous retroperitoneal implants were removed as completely as possible. Histologically, the tumor showed focal areas of capsular invasion, but free resection margins. The uterus and both ovaries were normal in appearance. No adjuvant therapy was pursued. Six months later, peritoneal and bilateral ovarian metastases were discovered.Hence, we report the details of this case of primary retroperitoneal mucinous cystadeno-carcinoma and present a review of the literature.

Citations

Citations to this article as recorded by  
  • MR Imaging of Primary Retroperitoneal Mucinous Cystadenocarcinoma in Pregnant Woman
    Jisun Lee, Bum Sang Cho, Yook Kim, Kyung Sik Yi, Min Ho Kang, Seung Young Lee, Sung Jin Kim, Kil Sun Park
    Journal of the Korean Society of Magnetic Resonance in Medicine.2013; 17(3): 243.     CrossRef
A Case of Pancreatic Acinar Cell Carcinoma.
Hwa Jung Lee, Jun Ho Ji, Seung Chan Park, Jung Chul Park, Eun Jung Choi, Hye Jin Seo, Won Sik Lee, Jung Lim Lee, Byung Jo Bae, Kyung Rak Shon, Kyung Hee Lee
Yeungnam Univ J Med. 2008;25(2):128-133.   Published online December 31, 2008
DOI: https://doi.org/10.12701/yujm.2008.25.2.128
  • 1,994 View
  • 1 Download
AbstractAbstract PDF
Acinar cell carcinoma is a rare tumor that represents 1~2% of all pancreatic cancers. Clinical and radiologic findings are inconclusive in this disease. Acinar cell carcinoma is characterized by rapid progression and early metastasis, which lead to its poor prognosis. A 41-year-old man was admitted to our hospital for abdominal pain. Abdominal computed tomography (CT) and positron emission tomography-computed tomography (PET-CT) showed a splenic mass, which was being invaded by a pancreatic tail mass and which had increased 18F-fluorodeoxyglucose (FDG) uptake. Primary radical distal pancreatectomy and splenectomy were performed. Pathologic findings revealed an acinar cell carcinoma of the pancreas. The patient underwent a total gastrectomy three months later because of gastric recurrence. Four months later, multiple hepatic metastases were discovered, and the patient underwent a left hepatectomy. During treatment with capecitabine, there was no evidence of tumor progression for 14 months. We report a case of metastatic pancreatic acinar cell carcinoma, which did not progress for an extended period while the patient was being treated with capecitabine.

JYMS : Journal of Yeungnam Medical Science
TOP